Aerie (AERI) September volatility at 190 into 'successful' efficacy results of Phase 3 Roclatan trial
- Wall Street ends higher, investors juggle Fed nerves with AI enthusiasm
- Apple in talks with Google to use generative AI in iPhones- Bloomberg
- World shares cheer China data, as central banks line up
- Oil prices climb 2% to 4-month high on lower Iraq, Saudi exports
- Meta Platforms is a new Top Pick at Mizuho, analyst sees upside to consensus
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Midday movers: Adobe, Zillow fall; Micron rises
- After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
- Midday movers: Tesla, Nvidia fall premarket; Robinhood, Dollar General rise
Aerie Pharma (AERI) Enters $50M Equity Offering Sales Agreement
September 15, 2016 6:12 AM EDTAerie Pharma (NASDAQ: AERI) disclosed the following in a U.S. SEC filing on Thursday:
Item 1.01. Entry into Material Definitive Agreement.
On September 15, 2016, Aerie Pharmaceuticals, Inc. (the Company) entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., acting as agent, pursuant to which the Company may offer and sell, from time to time... More